

(20426)

<b>Medical Benefit</b>		<b>Effective Date:</b> 01/01/13	<b>Next Review Date:</b> 07/19
<b>Preauthorization</b>	No	<b>Review Dates:</b> 09/12, 09/13, 07/14, 07/15, 07/16, 07/17, 07/18	

***This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.***

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>With suspected intestinal dysbiosis, irritable bowel syndrome, malabsorption or small intestinal bacterial overgrowth</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Fecal analysis testing</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard approach to diagnosing specific conditions</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Test accuracy</li> <li>Test validity</li> <li>Symptoms</li> <li>Functional outcomes</li> </ul>

### DESCRIPTION

Intestinal dysbiosis may be defined as a state of disordered microbial ecology that is believed to cause disease. Laboratory analysis of fecal samples is proposed as a method of identifying individuals with intestinal dysbiosis and other gastrointestinal disorders.

### SUMMARY OF EVIDENCE

For individuals who have suspected intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal bacterial overgrowth who receive fecal analysis testing, the evidence includes several cohort and case-control studies comparing fecal microbiota in patients who had a known disease with healthy controls. Relevant outcomes are test accuracy and validity, symptoms, and functional outcomes. The available retrospective cohort studies on fecal analysis have suggested that some components of the fecal microbiome and inflammatory markers may differ across patients with irritable bowel syndrome subtypes. No studies were identified on the diagnostic accuracy of fecal analysis vs. another diagnostic approach or compared health outcomes in patients managed with and without fecal analysis tests. No studies were identified that directly informed on the use of fecal analysis in the evaluation of intestinal dysbiosis, malabsorption, or small intestinal bacterial overgrowth. The evidence is insufficient to determine the effects of the technology on health outcomes.

### POLICY

Fecal analysis of the following components is considered **investigational** as a diagnostic test for the evaluation of intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal overgrowth of bacteria:

- Triglycerides
- Chymotrypsin
- Iso-butyrate, iso-valerate, and *n*-valerate
- Meat and vegetable fibers
- Long-chain fatty acids
- Cholesterol
- Total short-chain fatty acids
- Levels of Lactobacilli, bifidobacteria, and Escherichia coli and other “potential pathogens,” including Aeromonas, Bacillus cereus, Campylobacter, Citrobacter, Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella, Staphylococcus aureus, and Vibrio
- Identification and quantitation of fecal yeast (including Candida albicans, Candida tropicalis, Rhodotorula, and Geotrichum)
- *N*-butyrate
- $\beta$ -glucuronidase
- pH
- Short-chain fatty acid distribution (adequate amount and proportions of the different short-chain fatty acids reflect the basic status of intestinal metabolism)
- Fecal secretory immunoglobulin A.

## BACKGROUND

### INTESTINAL DYSBIOSIS

The gastrointestinal tract is colonized by a large number and variety of microorganisms including bacteria, fungi, and archaea. The concept of intestinal dysbiosis rests on the assumption that abnormal patterns of intestinal flora, such as overgrowth of some commonly found microorganisms, have an impact on human health. Symptoms and conditions attributed to intestinal dysbiosis include chronic disorders (e.g., irritable bowel syndrome, inflammatory or autoimmune disorders, food allergy, atopic eczema, unexplained fatigue, arthritis, ankylosing spondylitis), malnutrition, or neuropsychiatric symptoms (e.g., autism), and breast and colon cancer.

The gastrointestinal tract symptoms attributed to intestinal dysbiosis (i.e., bloating, flatulence, diarrhea, constipation) overlap in part with either irritable bowel syndrome or small intestinal bacterial overgrowth syndrome. The diagnosis of irritable bowel syndrome is typically made clinically, based on a set of criteria referred to as the Rome criteria. The small intestine normally contains a limited number of bacteria, at least as compared with the large intestine. Small intestine bacterial overgrowth may occur due to altered motility (including blind loops), decreased acidity, exposure to antibiotics, or surgical resection of the small bowel. Symptoms include malabsorption, diarrhea, fatigue, and lethargy. The laboratory criterion standard for diagnosis consists of the culture of a jejunal fluid sample, but this requires invasive testing. Hydrogen breath tests, commonly used to evaluate lactose intolerance, have been adapted for use in diagnosing small intestinal bacterial overgrowth.

### Fecal Markers of Dysbiosis

Laboratory analysis of both stool and urine has been investigated as markers of dysbiosis. Reference laboratories specializing in the evaluation of dysbiosis may offer comprehensive testing of various aspects of digestion,

absorption, microbiology, and metabolic markers. For example, Genova Diagnostics<sup>1</sup> offers the Comprehensive Digestive Stool Analysis 2.0 test, which evaluates a stool sample for components listed in Table 1.

Table 1. Components of the Comprehensive Digestive Stool Analysis 2.0 Test

Markers	Analytes
Digestion	<ul style="list-style-type: none"> <li>• Triglycerides</li> <li>• Chymotrypsin</li> <li>• Iso-butyrate, iso-valerate, and <i>n</i>-valerate</li> <li>• Meat and vegetable fibers</li> </ul>
Absorption	<ul style="list-style-type: none"> <li>• Long-chain fatty acids</li> <li>• Cholesterol</li> <li>• Total fecal fat</li> <li>• Total short-chain fatty acids</li> </ul>
Microbiology	<ul style="list-style-type: none"> <li>• Levels of Lactobacilli, bifidobacteria, and <i>Escherichia coli</i> and other “potential pathogens,” including <i>Aeromonas</i>, <i>Bacillus cereus</i>, <i>Campylobacter</i>, <i>Citrobacter</i>, <i>Klebsiella</i>, <i>Proteus</i>, <i>Pseudomonas</i>, <i>Salmonella</i>, <i>Shigella</i>, <i>Staphylococcus aureus</i>, and <i>Vibrio</i></li> <li>• Identification and quantitation of fecal yeast (including <i>Candida albicans</i>, <i>Candida tropicalis</i>, <i>Rhodotorula</i>, and <i>Geotrichum</i>)</li> </ul>
Metabolic	<ul style="list-style-type: none"> <li>• <i>N</i>-butyrate (considered key energy source for colonic epithelial cells)</li> <li>• <math>\beta</math>-glucuronidase</li> <li>• pH</li> <li>• Short-chain fatty acid distribution (adequate amount and proportions of the different short-chain fatty acids reflect the basic status of intestinal metabolism)</li> </ul>
Immunology	<ul style="list-style-type: none"> <li>• Fecal secretory immunoglobulin A (as a measure of luminal immunologic function)</li> <li>• Calprotectin</li> </ul>

The comprehensive stool analysis package has an optional parasitology component.

A related topic, fecal microbiota transplantation, the infusion of intestinal microorganisms to restore normal intestinal flora, is addressed in the Fecal Microbiota Transplantation Protocol. Fecal microbiota transplantation has been rigorously studied for the treatment of patients with recurrent *Clostridium difficile* infection. No specific stool testing, other than the identification of *Clostridium difficile* infection, is currently recommended.

## REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). The Genova Diagnostics test is available under the auspices of the CLIA. Laboratories that offer LDTs must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

## RELATED PROTOCOL

Fecal Microbiota Transplantation

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are

considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Genova Diagnostics. 2015; www.gdx.net. Accessed November 8, 2017.
2. Emmanuel A, Landis D, Peucker M, et al. Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome. *Frontline Gastroenterol.* Oct 2016;7(4):275-282. PMID 27761231
3. Goepf J, Fowler E, McBride T, et al. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. *Glob Adv Health Med.* May 2014;3(3):9-15. PMID 24891989
4. Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. *J Gastroenterol.* Dec 2012;47(12):1298-1307. PMID 22576027
5. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. *PLoS One.* Jan 27 2011;6(1):e16393. PMID 21297998
6. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut.* May 2011;60(5):631-637. PMID 21209126
7. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. *Am J Gastroenterol.* Jan 2008;103(1):162-169. PMID 17916108
8. Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. *Clin Chem Lab Med.* 2008;46(9):1275-1280. PMID 18597588
9. Schoepfer AM, Trummel M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. *Inflamm Bowel Dis.* Jan 2008;14(1):32-39. PMID 17924558
10. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. *World J Gastroenterol.* May 7 2008;14(17):2650-2661. PMID 18461650
11. Wilhelm SM, Brubaker CM, Varcak EA, et al. Effectiveness of probiotics in the treatment of irritable bowel syndrome. *Pharmacotherapy.* Apr 2008;28(4):496-505. PMID 18363533
12. Nikfar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. *Dis Colon Rectum.* Dec 2008;51(12):1775-1780. PMID 18465170
13. Jonkers D, Penders J, Masclee A, et al. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. *Drugs.* Apr 16 2012;72(6):803-823. PMID 22512365
14. Hungin AP, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. *Aliment Pharmacol Ther.* Oct 2013;38(8):864-886. PMID 23981066